vs
Orthofix Medical Inc.（OFIX）与SUPERIOR GROUP OF COMPANIES, INC.（SGC）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是SUPERIOR GROUP OF COMPANIES, INC.的1.5倍（$219.9M vs $146.6M），SUPERIOR GROUP OF COMPANIES, INC.净利率更高（2.4% vs -1.0%，领先3.4%），Orthofix Medical Inc.同比增速更快（2.0% vs 0.8%），SUPERIOR GROUP OF COMPANIES, INC.自由现金流更多（$17.9M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 2.7%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
舒必利尔集团（Superior Coach）曾是美国汽车工业的车身制造商，其前身加尔福德卡车公司成立于1909年。该企业最为人熟知的业务是打造灵车等专业车辆车身以及校车车身。受1970年代末两大业务板块的严重衰退影响，公司于1980年被母公司清算，1925年至1980年间，企业总部设于俄亥俄州利马市。
OFIX vs SGC — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $146.6M |
| 净利润 | $-2.2M | $3.5M |
| 毛利率 | 71.1% | 36.9% |
| 营业利润率 | 0.2% | 2.8% |
| 净利率 | -1.0% | 2.4% |
| 营收同比 | 2.0% | 0.8% |
| 净利润同比 | 92.4% | 65.8% |
| 每股收益（稀释后） | $-0.05 | $0.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $219.9M | $146.6M | ||
| Q3 25 | $205.6M | $138.5M | ||
| Q2 25 | $203.1M | $144.0M | ||
| Q1 25 | $193.6M | $137.1M | ||
| Q4 24 | $215.7M | $145.4M | ||
| Q3 24 | $196.6M | $149.7M | ||
| Q2 24 | $198.6M | $131.7M | ||
| Q1 24 | $188.6M | $138.8M |
| Q4 25 | $-2.2M | $3.5M | ||
| Q3 25 | $-22.8M | $2.7M | ||
| Q2 25 | $-14.1M | $1.6M | ||
| Q1 25 | $-53.1M | $-758.0K | ||
| Q4 24 | $-29.1M | $2.1M | ||
| Q3 24 | $-27.4M | $5.4M | ||
| Q2 24 | $-33.4M | $600.0K | ||
| Q1 24 | $-36.0M | $3.9M |
| Q4 25 | 71.1% | 36.9% | ||
| Q3 25 | 72.2% | 38.3% | ||
| Q2 25 | 68.7% | 38.4% | ||
| Q1 25 | 62.8% | 36.8% | ||
| Q4 24 | 69.0% | 37.1% | ||
| Q3 24 | 68.7% | 40.4% | ||
| Q2 24 | 67.8% | 38.5% | ||
| Q1 24 | 67.5% | 39.8% |
| Q4 25 | 0.2% | 2.8% | ||
| Q3 25 | -8.3% | 2.3% | ||
| Q2 25 | -7.9% | 1.3% | ||
| Q1 25 | -25.2% | -0.7% | ||
| Q4 24 | -5.3% | 1.7% | ||
| Q3 24 | -9.6% | 4.4% | ||
| Q2 24 | -12.5% | 0.5% | ||
| Q1 24 | -15.6% | 3.3% |
| Q4 25 | -1.0% | 2.4% | ||
| Q3 25 | -11.1% | 2.0% | ||
| Q2 25 | -6.9% | 1.1% | ||
| Q1 25 | -27.4% | -0.6% | ||
| Q4 24 | -13.5% | 1.4% | ||
| Q3 24 | -13.9% | 3.6% | ||
| Q2 24 | -16.8% | 0.5% | ||
| Q1 24 | -19.1% | 2.8% |
| Q4 25 | $-0.05 | $0.23 | ||
| Q3 25 | $-0.57 | $0.18 | ||
| Q2 25 | $-0.36 | $0.10 | ||
| Q1 25 | $-1.35 | $-0.05 | ||
| Q4 24 | $-0.76 | $0.12 | ||
| Q3 24 | $-0.71 | $0.33 | ||
| Q2 24 | $-0.88 | $0.04 | ||
| Q1 24 | $-0.95 | $0.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $23.7M |
| 总债务越低越好 | — | $94.1M |
| 股东权益账面价值 | $450.0M | $192.8M |
| 总资产 | $850.6M | $421.8M |
| 负债/权益比越低杠杆越低 | — | 0.49× |
8季度趋势，按日历期对齐
| Q4 25 | $82.0M | $23.7M | ||
| Q3 25 | $62.9M | $16.7M | ||
| Q2 25 | $65.6M | $21.0M | ||
| Q1 25 | $58.0M | $19.8M | ||
| Q4 24 | $83.2M | $18.8M | ||
| Q3 24 | $30.1M | $18.4M | ||
| Q2 24 | $26.4M | $13.4M | ||
| Q1 24 | $27.0M | $22.0M |
| Q4 25 | — | $94.1M | ||
| Q3 25 | $157.2M | $100.0M | ||
| Q2 25 | $157.0M | $99.3M | ||
| Q1 25 | $156.9M | $95.7M | ||
| Q4 24 | $157.0M | $86.0M | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
| Q4 25 | $450.0M | $192.8M | ||
| Q3 25 | $442.5M | $193.8M | ||
| Q2 25 | $458.3M | $192.1M | ||
| Q1 25 | $458.3M | $194.4M | ||
| Q4 24 | $503.1M | $198.9M | ||
| Q3 24 | $525.9M | $199.5M | ||
| Q2 24 | $546.0M | $200.9M | ||
| Q1 24 | $570.3M | $200.8M |
| Q4 25 | $850.6M | $421.8M | ||
| Q3 25 | $832.6M | $415.3M | ||
| Q2 25 | $837.2M | $423.3M | ||
| Q1 25 | $823.1M | $411.0M | ||
| Q4 24 | $893.3M | $415.1M | ||
| Q3 24 | $867.9M | $407.4M | ||
| Q2 24 | $882.0M | $400.3M | ||
| Q1 24 | $906.0M | $408.5M |
| Q4 25 | — | 0.49× | ||
| Q3 25 | 0.36× | 0.52× | ||
| Q2 25 | 0.34× | 0.52× | ||
| Q1 25 | 0.34× | 0.49× | ||
| Q4 24 | 0.31× | 0.43× | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $18.4M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $17.9M |
| 自由现金流率自由现金流/营收 | 7.6% | 12.2% |
| 资本支出强度资本支出/营收 | 4.9% | 0.4% |
| 现金转化率经营现金流/净利润 | — | 5.32× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $15.8M |
8季度趋势，按日历期对齐
| Q4 25 | $27.7M | $18.4M | ||
| Q3 25 | $12.4M | $-1.7M | ||
| Q2 25 | $11.6M | $4.9M | ||
| Q1 25 | $-18.4M | $-2.0M | ||
| Q4 24 | $23.7M | $8.9M | ||
| Q3 24 | $11.7M | $8.2M | ||
| Q2 24 | $9.0M | $6.9M | ||
| Q1 24 | $-18.6M | $9.4M |
| Q4 25 | $16.8M | $17.9M | ||
| Q3 25 | $2.5M | $-2.4M | ||
| Q2 25 | $4.5M | $3.3M | ||
| Q1 25 | $-25.1M | $-3.1M | ||
| Q4 24 | $15.2M | $7.4M | ||
| Q3 24 | $6.3M | $7.3M | ||
| Q2 24 | $-360.0K | $5.6M | ||
| Q1 24 | $-29.1M | $8.8M |
| Q4 25 | 7.6% | 12.2% | ||
| Q3 25 | 1.2% | -1.7% | ||
| Q2 25 | 2.2% | 2.3% | ||
| Q1 25 | -13.0% | -2.3% | ||
| Q4 24 | 7.0% | 5.1% | ||
| Q3 24 | 3.2% | 4.9% | ||
| Q2 24 | -0.2% | 4.2% | ||
| Q1 24 | -15.4% | 6.3% |
| Q4 25 | 4.9% | 0.4% | ||
| Q3 25 | 4.8% | 0.5% | ||
| Q2 25 | 3.5% | 1.1% | ||
| Q1 25 | 3.5% | 0.8% | ||
| Q4 24 | 4.0% | 1.0% | ||
| Q3 24 | 2.7% | 0.6% | ||
| Q2 24 | 4.7% | 1.0% | ||
| Q1 24 | 5.6% | 0.5% |
| Q4 25 | — | 5.32× | ||
| Q3 25 | — | -0.61× | ||
| Q2 25 | — | 3.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.28× | ||
| Q3 24 | — | 1.52× | ||
| Q2 24 | — | 11.42× | ||
| Q1 24 | — | 2.41× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
SGC
| Branded Products | $96.9M | 66% |
| Healthcare Apparel | $28.8M | 20% |
| Contact Centers | $21.7M | 15% |
